TLR5 and graft versus host disease: 15 In this study, we found that priming with a TLR5 agonist allowed MSCs to act as a therapeutic agent even in low grade inflammation, which is the predominant environment in a clinic, and induced polarization of M2 macrophages, which was not found in previous studies, alleviating GVHD.